|Privately held naamloze vennootschap; subsidiary|
|Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)|
|Products||Vaccines and antibodies|
|Revenue||€329.8 million (2010)|
|(€34.3 million) (2010)|
|Profit||(€27.6 million) (2010)|
|Total assets||€967.1 million (end 2010)|
|Total equity||€786.4 million (end 2010)|
|Owner||Johnson & Johnson|
Number of employees
Crucell is a biotechnology company specializing in vaccines and biopharmaceutical technologies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands. Crucell shares were previously listed on the Euronext Amsterdam exchange and formed part of the AMX index until April 2011, when J&J completed a tender offer for the company.
In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.
In 2006, Crucell and Swiss Berna Biotech, Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.
On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine. This follows in the wake of Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J agreed to acquire the rest of the company in October 2010, taking its stake to over 95% by February 2011 and delisting the company from stock exchanges two months later.
Crucell has received U.S. National Institutes of Health (NIH) funding to develop Ad26.ZEBOV, a potential vaccine that would protect against both the Ebola virus disease hemorrhagic fever (from the Ebola virus; the causative agent of the 2014 Ebola outbreak in western Africa- the largest ever of the disease, with at least 1,000 deaths), and Marburg hemorrhagic fever (from the Marburg virus), which produces similar symptoms because both are hemorrhagic fever diseases. The prognosis for both, especially without early accurate diagnosis and modern treatments and care standards, is usually quite poor. The Ad26.ZEBOV potential vaccine followed by a second vaccine (MVA-BN from Bavarian Nordic) as boost completed Phase 1 trials in 2015 and Phase 2 trials were planned for 2016.
Travel and endemic
- Inflexal V
- "Annual Results 2010" (PDF). Crucell. Retrieved 27 February 2011.
- "Annual Report 2009" (PDF). Crucell. Retrieved 2010-05-23.
- "five core proprietary technology platforms". http://www.crucell.com/. Retrieved 29 Oct 2014. External link in
- Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
- Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
- Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.
- "Two-vaccine Ebola regimen shows promise in early-stage clinical trial". Medical Xpress. 2016-05-19. Retrieved 2016-06-09.
- "J&J starts vaccine trial in Sierra Leone, even as Ebola fades". Reuters. 2015-10-09. Retrieved 2016-06-09.
- "MHRP, WRAIR Begin New Phase 2 Clinical Trial of Ebola Vaccine Regimens". MHRP - US Military HIV Research Program. 2016-01-01. Retrieved 2016-06-09.